RED LIGHT HOLLAND CORP - TRUFF STOCK NEWS

Red Light Holland Corp. announces the launch of its Fresh Mushroom Sales Division, SR Wholesale North America, in partnership with Holburne and F&R Mushroom farms. The company aims to expand its product offerings and market presence by focusing on the sale of high-quality fresh mushrooms, aligning with its mission to contribute to the growth of the exotic fresh mushroom and emerging psychedelics markets. The launch of SR Wholesale North America is expected to meet the increasing demand for natural, health-conscious products and position Red Light Holland as a key player in the evolving industry.

Red Light Holland's psilocybin microdosing capsules, developed from truffles grown in the Netherlands, have received final Product Specification document signed by CCrest Laboratories. The capsules are free of pesticides, bio contaminants, and heavy metals. The company plans to import psilocybin truffles into Canada and connect with NUBU's network of medical doctors in Australia and New Zealand.

Red Light Holland Corp. (CSE: TRIP) announces a new multi-million dollar production facility to increase AEM Farm's mushroom production output by approximately 15-18 million dollars of domestic and international annual sales. The 80,000 square foot state-of-the-art vertical exotic mushroom farm and composting facility is expected to produce over 15,000 tons of mushroom compost annually, leading to more than 7,500,000 pounds of fresh mushrooms per year. The facility will support the Company's global and local operations with high-quality, large-scale exotic mushroom production capabilities. CEO Todd Shapiro emphasizes the company's commitment to growing the psychedelic side of their business. Red Light Holland also plans to share details and updates regarding its partnership with CCrest Labs and NUBU Pharmaceuticals, increasing production and output in the Company's Magic Truffle Farm in Horst, the Netherlands, and its Mushroom Home Grow Kit division. The company has total assets of $28.2 million, including $16.4 million of cash and cash equivalents.

Red Light Holland (TRIP) confirms stability of psilocybin in natural microdosing capsules after five months of tests, following the completion of Certificate Of Analysis. The company plans to import more truffles into Canada and collaborate with Nubu's network of medical doctors.

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announced financial highlights for the three and six months ended September 30, 2023, including a cash balance of $16.4 million, revenue of $1.0 million (a 33.5% increase from 2022), gross profit of $0.4 million (a 20.0% increase from 2022), property, plant and equipment value of $5.1 million, and total assets of $28.2 million.

Red Light Holland Corp. (CSE: TRIP) announces the re-engagement of the Honourable Tony P. Clement as Senior Advisor to its Advisory Board. Mr. Clement, a prominent figure in politics, law, and business, will provide strategic advice on compliance, lobbying efforts for international expansion, and potential Canadian expansion. He will also assist with investor relations, emphasizing the company's commitment to mental health and wellness. The re-engagement signifies the company's focus on assembling skilled leaders for early-stage industry growth.

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announces successful stability testing for natural psilocybin microdosing capsules, paving the way for distribution in Australia and New Zealand.

Red Light Holland Corp. has appointed Troy DuFour as Senior Vice President of Sales. DuFour brings over 24 years of commercial strategy experience with consumer-focused organizations. He will support the company's growth initiatives and focus on increasing mushroom sales to drive revenue growth. Red Light Holland is dedicated to expanding its mushroom sales and home grow kits division.

Red Light Holland Corp. has engaged Dr. Taras Nahirny as an Advisor to the Company. Dr. Nahirny will provide consulting services in various areas, including the development of medical grade psilocybin microdosing capsules, exploring the use of microdosing capsules with patients in Canada, collecting data on the therapeutic benefits of Psilocybin, and promoting collaborations with medical companies. The company has also granted stock options to certain consultants.